Women who were treated for pelvic organ prolapse (POP) using Coloplast Ltd. transvaginal mesh experienced similar outcomes at 36 months to those treated with native tissue repair, the US Food and Drug Administration said on 17 October.
Coloplast Vaginal Mesh Postmarket Data Shows Similar Safety To Native Tissue Repair
The company’s review of patient safety data found similar adverse event rates between patients treated with transvaginal mesh and those treated surgically. However, the FDA still says the benefits of the treatment do not outweigh its risks
More from Regulation
More from Policy & Regulation
• By
A planned merger between medical device coating manufacturers Surmodics and Biocoat is facing an antitrust lawsuit from the US Federal Trade Commission. The FTC believes the move would create an illegal monopoly.
• By
Democrats are raising concerns that the continuing resolution intended to fund the government for the remainder of fiscal year 2025 gives Trump too much power, though it is unclear whether the FDA would be as impacted as other agencies.
• By
The European Commission has published a 44-page EHDS Q&A while industry has issued a joint paper emphasizing the importance of a stakeholder forum just as the EHDS Regulation is published and is due to enter into force.